Is the very low carbohydrate diet safe for individuals with chronic kidney disease?
Journal of Metabolic Health (previously Journal of Insulin Resistance)
| Field | Value | |
| Title | Is the very low carbohydrate diet safe for individuals with chronic kidney disease? | |
| Creator | Colledge, Brooke S. Schofield, Emma C. Clarke, Benjamin J. Popovic, Gordana Vattekad, Mohandas Figtree, Penelope E. | |
| Description | Background: The very low carbohydrate diet (VLCHD) is gaining popularity as a therapy for metabolic syndrome. However, its effect on renal function in patients with comorbid moderate to severe chronic kidney disease (CKD) is currently unclear.Aim: This study analyses markers of kidney function in patients with metabolic syndrome and stages 3 and 4 CKD who undertook a VLCHD for at least 3 months.Setting: The study was conducted in a Mid North Coast general practice located in Port Macquarie, NSW, Australia, 2020–2022.Methods: Clinical data were analysed retrospectively from 18 participants with metabolic syndrome and CKD stages 3 and 4, who were prescribed a VLCHD ( 30 g carbohydrates/day). A linear mixed model was used to analyse markers of metabolic health (glycated haemoglobin (HbA1C), body mass index (BMI), blood pressure (BP), lipid profile (triglycerides and low-density lipoprotein cholesterol) and kidney function (estimated glomerular filtration rate (eGFR), serum creatinine, bicarbonate and urea)).Results: Strong evidence was found for reduced BMI (p 0.001) and HbA1c (p 0.001), despite reduced diabetic medications in 13/14 participants. Antihypertensive medications were reduced in 6/14 participants with no change in systolic BP. No changes were detected in eGFR or bicarbonate, while creatinine (p ≤ 0.001) and urea (p = 0.002) were reduced. No participants deteriorated to a more advanced stage of CKD; rather an absolute eGFR increase was found in 15/18 participants.Conclusion: For the first time, the VLCHD was demonstrated to reduce BMI, HbA1c, BP and medication burden in patients with CKD stages 3–4 without evidence of kidney damage.Contribution: The VLCHD could be a safe and effective therapy to improve metabolic health and consequently reduce cardiovascular disease risk in patients with metabolic syndrome and CKD. | |
| Publisher | AOSIS | |
| Date | 2025-02-27 | |
| Identifier | 10.4102/jmh.v8i1.115 | |
| Source | Journal of Metabolic Health; Vol 8, No 1 (2025); 10 pages 2960-0391 3105-4323 | |
| Language | eng | |
| Relation |
The following web links (URLs) may trigger a file download or direct you to an alternative webpage to gain access to a publication file format of the published article:
https://journalofmetabolichealth.org/index.php/jmh/article/view/115/363
https://journalofmetabolichealth.org/index.php/jmh/article/view/115/364
https://journalofmetabolichealth.org/index.php/jmh/article/view/115/365
https://journalofmetabolichealth.org/index.php/jmh/article/view/115/367
|
|
ADVERTISEMENT
